Novo Nordisk (NVO) is now offering its GLP-1 weight-loss drug Wegovy at half its price, amounting to $499 per month.

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

Weight-loss drugs are changing the way people grocery shop and eat. But those spending habits don't necessarily last.

Patients using GLP-1 drugs had no difference in the odds of postoperative aspiration pneumonia versus non-users. Preoperative ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration ...

GLP-1 drugs on the market include Novo Nordisk's diabetes drug Ozempic, its weight-loss treatment Wegovy and Eli Lilly's (LLY.N), opens new tab obesity drug Zepbound. But the class of drugs ...